HBR

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

Retrieved on: 
Thursday, September 22, 2022
Benchmark, Adult, Carbapenem, Meiji, Infection, Sinusitis, Biomedical Advanced Research and Development Authority, COVID-19, FDA, Food, Otitis media, Administration, Gram, U.S. Securities and Exchange Commission, Company, Genta (company), GSK, Access, Degenerative disease, AP, Therapy, Program, Patient, Cyprus Securities and Exchange Commission, Pneumonia, Technology, Pyelonephritis, Human services, QIDP, Tebipenem, Bacteria, Annual report, Hart–Scott–Rodino Antitrust Improvements Act, Urinary tract infection, Research, HBR, Marketing, Cutis marmorata telangiectatica congenita, Food and Drug Administration, Gram-negative bacteria, Disease, Pharmaceutical industry, Spero

LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agreement for Spero’s late-stage antibiotic asset, tebipenem HBr. Tebipenem HBr is being developed as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.

Key Points: 
  • In connection with the license agreement and pursuant to a stock purchase agreement between GSK and Spero, GSK has agreed to make a $9 million common stock investment in Spero, purchasing 7,450,000 shares of Speros common stock at a purchase price of approximately $1.20805 per share, not to exceed 19.99% beneficial ownership of Spero by GSK and its affiliates.
  • The closing of the equity investment is conditioned upon the effectiveness of the license following Hart-Scott-Rodino clearance.
  • As of June 30, 2022, Spero had cash, cash equivalents, and marketable securities of $45.4 million.
  • If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States.

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

Retrieved on: 
Thursday, September 15, 2022
Adult, American University, MPH, American University of Beirut, Roivant Sciences, Time, Joint Medical Service (Germany), American College, COVID-19, Infection, Risk, FDA, Urinary tract infection, U.S. Securities and Exchange Commission, Basilea Pharmaceutica, Degenerative disease, Partnership, CMO, Therapy, Medical Affairs Bureau, Program, Patient, University, MBA, Bristol Myers Squibb, Physician, American College of Physicians, Tebipenem, Nasdaq, Stanford University School of Medicine, Novartis, Internal medicine, Johns Hopkins University, Pyelonephritis, Research, GLOBE, HBR, Cutis verticis gyrata, Infectious Diseases Society of America, Robert Wood Johnson Medical School, Pharmaceutical industry, MD, Bayer, Aleksei Lysov, Spero

CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO).

Key Points: 
  • CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO).
  • Kamal joins Spero with an impressive track record of building and leading successful anti-infective franchises, said Ankit Mahadevia, MD, Chief Executive Officer of Spero Therapeutics.
  • I am thrilled to have Kamal on our management team and look forward to working together.
  • Dr. Hamed has over 20 years of experience leading various anti-infective clinical development programs in antibacterials, antivirals, antimalarials, and antifungals.

Fullcast Introduces Powerful 'Smart' Territory Planning

Retrieved on: 
Wednesday, September 14, 2022
GTM, Agility, Entrepreneurship, HBR, CRM, Capital punishment, Exercise, ARR, Geography, CEO, GLOBE, Surveying

REDMOND, Wash., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Fullcast, the industry's only RevOps platform for GTM Planning and Execution, today announced the launch of its new SmartPlan territory planning engine.

Key Points: 
  • REDMOND, Wash., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Fullcast, the industry's only RevOps platform for GTM Planning and Execution, today announced the launch of its new SmartPlan territory planning engine.
  • SmartPlan enables Fullcast users to reduce hands-on-keyboard territory planning time from weeks to as little as 30 minutes.
  • "SmartPlan is a major advance for RevOps teams conducting territory planning," commented Dharmesh Singh, CEO and Co-Founder at Fullcast.
  • About Fullcast - Fullcast is the only RevOps Platform that seamlessly connects GTM planning with tactical execution.

Spero Therapeutics to Present at Upcoming Investor Conference

Retrieved on: 
Wednesday, September 7, 2022
Spero, Degenerative disease, Therapy, HBR, Infection, Tebipenem, Cutis verticis gyrata, GLOBE, Conference, Nasdaq, FDA, Pyelonephritis, Adult, MDR, Patient, Pharmaceutical industry

Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.

Key Points: 
  • Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.
  • Spero Therapeuticsis a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
  • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Retrieved on: 
Tuesday, September 6, 2022
Type, Partnership, COVID-19, Biomedical Advanced Research and Development Authority, NDA, Program, Urinary tract infection, Research, Degenerative disease, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, HBR, Infection, Tebipenem, North Carolina Department of Health and Human Services, Administration, Cutis verticis gyrata, Food, Department, U.S. Securities and Exchange Commission, SPA, GLOBE, Nasdaq, FDA, Pyelonephritis, CRL, Adult, Risk, Endpoint security, Marketing, Patient, Medical device, Pharmaceutical industry, Spero

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
  • We are pleased to have found common ground with the FDA on the regulatory path forward for tebipenem HBr, said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
  • With this clarity, we are better positioned to advance the program as we work to establish and nurture external partnerships for further development.
  • However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

HBR Consulting's Continued Growth Recognized Again in Inc. 5000 List of Nation's Fastest Growing Private Companies

Retrieved on: 
Thursday, August 18, 2022
Risk, HBR, CEO, Technology, Growth, Investment, Environment, Twitter, AM, Trust, Partnership, Private law, Crain's Chicago Business, LinkedIn, Organization, Pharmaceutical industry, Public relations

CHICAGO, Aug. 18, 2022 /PRNewswire/ -- HBR Consulting LLC (HBR), a trusted advisor to law firms and law departments, has been recognized on the Inc. 5000 list of the fastest growing private companies in America, joining an elite group of organizations that made the prestigious list for four consecutive years. Based on three-year revenue growth, the list of the nation's most successful private companies has become the hallmark of entrepreneurial success.

Key Points: 
  • Based on three-year revenue growth, the list of the nation's most successful private companies has become the hallmark of entrepreneurial success.
  • Earlier this year, HBR was included in Crain's Chicago Business' "Fast 50," the publication's list of the fastest-growing companies in the region, whether publicly traded or privately held.
  • This is HBR's second year to be recognized on that list, which is based on five-year revenue growth.
  • "We are delighted to again be recognized on Inc. 5000's annual list," said Nick Quil, HBR's CEO.

Legal Industry Leader HBR Managed Services Partners with Tanium to Enhance Security and IT Services Capabilities

Retrieved on: 
Monday, August 15, 2022
Cloud, Security, Risk, HBR, NOC, Industry, Fortune, OS, Compliance, SVP, Forbes, Environment, Twitter, Partnership, Workflow, LinkedIn, Risk management, Technology, Tanium

CHICAGO, Aug. 15, 2022 /PRNewswire/ -- HBR Managed Services (HBR), a comprehensive strategy, operations and technology consulting firm focused on the legal industry, today announced its partnership with Tanium, the industry's only provider of converged endpoint management (XEM) for complex security and technology environments.

Key Points: 
  • CHICAGO, Aug. 15, 2022 /PRNewswire/ -- HBR Managed Services (HBR), a comprehensive strategy, operations and technology consulting firm focused on the legal industry, today announced its partnership with Tanium , the industry's only provider of converged endpoint management (XEM) for complex security and technology environments.
  • "That's critical in today's hybrid environment, allowing us to quickly prevent or remediate security or other operational issues by deploying registry changes and executing scripts."
  • "Tanium is keenly aware of the heightened risks the industry faces and we are proud to align with a leader like HBR as they work to secure the interests of their clients.
  • "We're pleased to add Tanium to our roster of best-in-class vendor partners," added Chris Petrini-Poli, HBR's executive chairman.

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

Retrieved on: 
Tuesday, August 9, 2022
FDA, Spero, HBR, GLOBE, Tebipenem, Pyelonephritis, Patient, Infection, Degenerative disease, Therapy, Tuberculosis verrucosa cutis, Nasdaq, ID, Adult, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m.
  • ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.
  • To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

New Harvard Business Review Analytic Services Research Finds Effective Customer Engagement is Business Critical Amid Economic Uncertainty

Retrieved on: 
Monday, July 25, 2022
Theodore Levitt, Intelligence, Business, Social capital, HBR, Customer, CEO, SAN, Culture, Research, Qualitative research, Organization, Defence Analytical Services and Advice, Marketing, Harvard Business Review, Internet, Technology, Bessemer Venture Partners, Intercom, Health, Amazon, Growth, Engagement, Public relations, Sales, Management, Atlassian

SAN FRANCISCO, July 25, 2022 /PRNewswire/ -- Today, Harvard Business Review Analytic Services released a new report sponsored by Intercom, the Engagement OS, called "Future-Proofing Businesses with Modern Customer Engagement," which reveals a significant gap in how companies are engaging with their customers. This comes at a time when delivering exceptional experiences is even more critical to retention and revenue, amidst both an economic downturn and increasingly competitive landscape.

Key Points: 
  • Additionally, 92% view effective customer engagement as "very" to "extremely'' critical to their organization's success, but only 9% say they have excellent engagement today.
  • "This research shows that while business leaders understand the importance of customer engagement, they are encountering barriers in execution," said Alex Clemente, Managing Director of Analytic Services at Harvard Business Review.
  • The findings on the value of customer engagement are based on a global survey fielded in April 2022 of 317 business leaders conducted by Harvard Business Review Analytic Services.
  • Harvard Business Review Analytic Services is an independent commercial research unit within Harvard Business Review Group, conducting research and comparative analysis on important management challenges and emerging business opportunities.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Friday, July 22, 2022
Class Action Lawsuit, Professional Services, Legal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Time, Tebipenem, Court, Food, Twitter, Law, Workforce, NDA, HBR, Therapy, New Drug Application, NASDAQ, Urinary tract infection, News, Review, FDA, Company, Defendant, Lists of schools in England, Suite, Pharmaceutical industry, Spero

On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.

Key Points: 
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • If you purchased or otherwise acquired Spero securities during the Class Period, you may move the Court no later than July 25, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.